Virological response to Salvage Therapy in HIV-Infected Persons Carrying the Reverse Transcriptase K65R Mutation

Abstract

Background

The effect of the HIV reverse transcriptase K65R mutation on virological response to salvage therapy has not been clearly defined.

Methods

From six Italian clinical centres, all consecutive patients starting salvage antiretroviral therapy after virological failure in the presence of the K65R mutation identified by a genotypic resistance test were selected.

Results

Among 145 subjects included over a 197 person-year follow-up, the estimated probability of virological response (VR, defined as reaching HIV RNA <50 copies/ml after salvage therapy) at 24 and 48 weeks was 36% and 60%, respectively. The strongest independent predictor of VR was the inclusion of a thymidine analogue (TA) in the salvage regimen. The presence of M184V and the introduction of lopinavir/ritonavir as new drug were both marginally associated with better outcome. After 24 weeks of salvage therapy, the median reduction in HIV-1 RNA was -1.36 log₁₀ copies/ml (interquartile range [IQR] 0.10–2.46): at multivariable regression analysis, salvage regimens containing a TA (β=+0.80; P=0.02) and lamivudine (β=+1.21; P=0.02) as new drug had a positive effect on the reduction of HIV-1 RNA.

Conclusions

Development of the K65R mutation does not preclude a high rate of virological response to rescue therapy. Inclusion of a TA in the salvage regimen and the presence of a M184V mutation could have a favourable effect on virological outcome.

References

Wainberg

M.A.

, Miller

M.D.

, Quan

In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA.

Antivir Ther 1999; 4: 87–94.

, Gao

, Fang

Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2’,3’-dideoxycytidine and 2’,3’-dideoxy-3’-thiacytidine.

Antimicrob Agents Chemother 1994; 38: 275–281.

Zhang

, Caliendo

A.M.

, Eron

J.J.

Resistance to 2’,3’-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase.

Antimicrob Agents Chemother 1994; 38: 282–287.

Winston

, Pozniak

, Mandalia

, Gazzard

, Pillay

, Nelson

Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase.

AIDS 2004; 18: 949–957.

Trotta

M.P.

, Bonfigli

, Ceccherini-Silberstein

Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovir.

J Med Virol 2006; 78: 535–541.

Kagan

R.M.

, Merigan

T.C.

, Winters

M.A.

, Heseltine

P.N.

Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization.

Antivir Ther 2004; 9: 827–828.

Valer

, Martin-Carbonero

, deMendoza

, Corral

, Soriano

Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations.

AIDS 2004; 18: 2094–2096.

Segondly

, Montes

Prevalence and conditions of selection of the K65R mutation in the reverse transcriptase gene of HIV-1.

J Acquir immune Defic Syndr 2005; 38: 110–111.

Parikh

U.M.

, Bacheler

, Koontz

, Mellors

J.W.

The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations.

J Virol 2006; 80: 4971–4977.

10.

Gallant

J.E.

, Staszewski

, Pozniak

A.L.

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

JAMA 2004; 292: 191–201.

11.

McColl

D.J.

, Margot

N.A.

, Wulfsohn

, Coakley

D.F.

, Cheng

A.K.

, Miller

M.D.

Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate.

J Acquir Immune Defic Syndr 2004; 37: 1340–1350.

12.

White

K.L.

, Margot

N.A.

, Ly

J.K.

A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT.

AIDS 2005; 19: 1751–1760.

13.

White

K.L.

, Chen

J.M.

, Feng

J.Y.

The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations.

Antivir Ther 2006; 11: 155–163.

14.

Bazmi

H.Z.

, Hammond

J.L.

, Cavalcanti

S.C.

, Chu

C.K.

, Schinazi

R.F.

, Mellors

J.W.

In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-β-d-dioxolane-guanosine and suppress resistance to 3’-azido-3’-deoxythymidine.

Antimicrob Agents Chemother 2000; 44: 1783–1788.

15.

Johnson

V.A.

, Brun-Vezinet

, Clotet

Update of the drug resistance mutations in HIV-1: Fall 2005.

Top HIV Med 2005; 13: 125–131.

16.

Flandre

, Descamps

, Joly

Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received.

Antivir Ther 2003; 8: 65–72.

17.

Cozzi-Lepri

, Ruiz

, Loveday

Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy.

Antivir Ther 2005; 10: 791–802.

18.

De Luca

, Di Giambenedetto

, Romano

Frequency and treatment-related predictors of thymidine-analogue mutation patterns in HIV-1 isolates after unsuccessful antiretroviral therapy.

J Infect Dis 2006; 193: 1219–1222.

19.

The HIV RT and protease sequences database at Stanford at Stanford University; (updated 1 July 2007). Available from http://hivdb.stanford.edu.

20.

van Laethem

, De Luca

, Antinori

, Congolani

, Perno

C.F.

, Vandamme

A.M.

A genotypic drug resistance algorithm that significantly predicts therapy response in HIV-1-infected patients.

Antivir Ther 2002; 7: 123–129.

21.

Landman

, Descamps

, Peytavin

Early virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial treatment of HIV-1 infection: TONUS study.

HIV Clin Trials 2005; 6: 291–301.

22.

Nevis

A.B.

, Wirden

, Rhee

S.Y.

Virological response to antiretroviral therapy in the setting of the K65R mutation.

Antivir Ther 2006; 11: S92.

23.

Weber

, Chakraborty

, Weberova

, Miller

M.D.

, Quinones-Mateu

M.E.

Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation.

J Clin Microbiol 2005; 43: 1395–1400.

24.

Margot

N.A.

, Isaacson

, McGowan

, Cheng

A.K.

, Schooley

R.T.

, Miller

M.D.

Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF.

AIDS 2002; 16: 1227–1235.

25.

Squires

, Pozniak

A.L.

, Pierone

Jr.

Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infecton.

Ann Intern Med 2003; 139: 313–320.

26.

DART Virology Group and Trial Team.

Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa.

AIDS 2006; 20: 1391–1399.

27.

Balestre

, Dupon

, Capdepont

Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort.

J Clin Virol 2006; 36: 95–99.

28.

Khanlou

, Guyer

, Farthing

Efficacy of tenofovir as intensification of zidovudine/lamivudine/abacavir fixed-dose combination in the treatment of HIV-positive patients.

J Acquir Immune Defic Syndr 2005; 38: 627–628.

29.

Garcia-Lerma

J.G.

, MacInnes

, Bennett

A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation.

J Virol 2003; 77: 5685–5693.

30.

Agence Nationale de Recherches sur le SIDA, groupe AC11; (updated 20 July 2006). Available from: http://www.hivfrenchresistance.org/tab2005.html.

31.

Blanco

J.L.

, Teniente

, Mallolas

Relation between antiretroviral activity of stavudine (d4T) and number of reverse transcriptase (RT) mutations: ZENAM study.

Antivir Ther 2006; 11 Suppl 1: S96.

32.

Roge

B.T.

, Katzenstein

T.L.

, Obel

K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.

Antivir Ther 2003; 8: 173–182.

33.

Svicher

, Sing

, Santoro

M.M.

Involvement of novel HIV-1 reverse transcriptase mutations in the regulation of resistance nucleoside inhibitors.

J Virol 2006; 80: 7186–7198.

34.

Larder

B.A.

, Kemp

S.D.

, Harrigan

P.R.

Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.

Science 1995; 269: 696–999.

35.

Wainberg

M.A.

, Miller

M.D.

, Quan

In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA.

Antivir Ther 1999; 4: 87–94.

36.

Wolf

, Walter

, Beerenwinkel

Tenofovir resistance and resensitization.

Antimicrob Agents Chemother 2003; 47: 3478–3484.

37.

Harrigan

P.R.

, Miller

M.D.

, McKenna

, Brumme

Z.L.

, Larder

B.A.

Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates.

Antimicrob Agents Chemother 2002; 46: 1067–1072.

38.

White

K.L.

, Margot

N.A.

, Wrin

, Petropoulos

C.J.

, Miller

M.D.

, Naeger

L.K.

Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity.

Antimicrob Agents Chemother 2002; 46: 3437–3446.

39.

Deval

, White

K.L.

, Miller

M.D.

Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations.

J Biol Chem 2004; 279: 509–516.

40.

Kempf

D.J.

, King

M.S.

, Bernstein

Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.

J Infect Dis 2004; 189: 51–60.

41.

Hammer

S.M.

, Vaida

, Bennett

K.K.

Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.

JAMA 2002; 288: 169–180.

42.

Weidle

P.J.

, Lichtenstein

K.A.

, Moorman

A.C.

Factors associated with the successful modification of antiretroviral therapy. HIV Outpatient Study Investigators.

AIDS 2000; 14: 491–497.

43.

Ciancio

B.C.

, Trotta

M.P.

, Lorenzini

The effect of number of mutations and of drug-class sparing on virological response to salvage genotype-guided antiretroviral therapy.

Antivir Ther 2003; 8: 611–616.

44.

Brenner

B.G.

, Oliveira

, Doualla-Bell

HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture.

AIDS 2006; 20: F9–F13.